Cargando…

Diabetes and Cardiovascular Complications: The Epidemics Continue

PURPOSE OF REVIEW: The cardiovascular complications of type 1 and 2 diabetes are major causes of morbidity and mortality. Extensive efforts have been made to maximize glycemic control; this strategy reduces certain manifestations of cardiovascular complications. There are drawbacks, however, as inte...

Descripción completa

Detalles Bibliográficos
Autores principales:	López-Díez, Raquel, Egaña-Gorroño, Lander, Senatus, Laura, Shekhtman, Alexander, Ramasamy, Ravichandran, Schmidt, Ann Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Diabetes and Cardiovascular Disease (D Bruemmer, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173334/ https://www.ncbi.nlm.nih.gov/pubmed/34081211 http://dx.doi.org/10.1007/s11886-021-01504-4

Ejemplares similares

Continuous Glucose Monitor, Insulin Pump, and Automated Insulin Delivery Therapies for Type 1 Diabetes: An Update on Potential for Cardiovascular Benefits
por: Pauley, Meghan E., et al.
Publicado: (2022)

Comprehensive Care Models for Cardiometabolic Disease
por: Reiter-Brennan, Cara, et al.
Publicado: (2021)

Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic Opportunities in Diabetes and Cardiovascular Disease: Insights From Human Subjects and Animal Models
por: Egaña-Gorroño, Lander, et al.
Publicado: (2020)

Inflammation Meets Metabolism: Roles for the Receptor for Advanced Glycation End Products Axis in Cardiovascular Disease
por: Senatus, Laura, et al.
Publicado: (2021)

Glycation and a Spark of ALEs (Advanced Lipoxidation End Products) – Igniting RAGE/Diaphanous-1 and Cardiometabolic Disease
por: Arivazhagan, Lakshmi, et al.
Publicado: (2022)

Hypoglycemia and Cardiovascular Risks
por: Frier, Brian M., et al.
Publicado: (2011)

Glucose Control and Cardiovascular Disease: Is it important? No
por: Conget, Ignacio, et al.
Publicado: (2009)

Is Hyperglycemia a Cardiovascular Risk Factor?
por: Pistrosch, Frank, et al.
Publicado: (2011)

Endothelial Dysfunction as a Target for Prevention of Cardiovascular Disease
por: Versari, Daniele, et al.
Publicado: (2009)

Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No
por: Kassem, Sameer A., et al.
Publicado: (2009)

Getting to the “Heart” of the Matter on Diabetic Cardiovascular Disease: “Thanks for the Memory”
por: Cefalu, William T., et al.
Publicado: (2016)

Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes
por: Bianchi, Cristina, et al.
Publicado: (2009)

Is Hyperglycemia a Causal Factor in Cardiovascular Disease?: Does proving this relationship really matter? Yes
por: Davidson, Jaime A., et al.
Publicado: (2009)

Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study
por: Gori, Mauro, et al.
Publicado: (2016)

DIAPH1 mediates progression of atherosclerosis and regulates hepatic lipid metabolism in mice
por: Senatus, Laura, et al.
Publicado: (2023)

The Munich Myocardial Infarction Registry: Translating the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) guidelines on diabetes, pre-diabetes, and cardiovascular disease into clinical practice
por: Schnell, Oliver, et al.
Publicado: (2009)

A CARDIOVASCULAR COMPLICATION OF COVID-19: DELAYED PRESENTATION OF ACUTE MYOPERICARDITIS
por: Akula, Navya, et al.
Publicado: (2020)

The RAGE/DIAPH1 Signaling Axis & Implications for the Pathogenesis of Diabetic Complications
por: Ramasamy, Ravichandran, et al.
Publicado: (2022)

The value of pregnancy complication history for 10-year cardiovascular disease risk prediction in middle-aged women
por: Timpka, Simon, et al.
Publicado: (2018)

Shifting the Disease Management Paradigm From Glucose: What are the pros?
por: Stirban, Alin, et al.
Publicado: (2009)

A Summary of the ADVANCE Trial
por: Heller, Simon R.
Publicado: (2009)

Implications of Postprandial Glucose and Weight Control in People With Type 2 Diabetes: Understanding and implementing the International Diabetes Federation guidelines
por: Gallwitz, Baptist
Publicado: (2009)

Shifting the Disease Management Paradigm From Glucose: What are the cons?
por: Hanefeld, Markolf, et al.
Publicado: (2009)

Postprandial Hyperglycemia and Glycemic Variability: Should we care?
por: Standl, Eberhard, et al.
Publicado: (2011)

Heart in Diabetes: Not Only a Macrovascular Disease
por: Stratmann, Bernd, et al.
Publicado: (2011)

Heart in Diabetes: A Microvascular Disease
por: Laakso, Markku
Publicado: (2011)

Antiplatelet Therapy for Every Diabetic Person?
por: Nicolucci, Antonio, et al.
Publicado: (2011)

Should C-Reactive Protein Be a Target of Therapy?
por: Oh, Jisun, et al.
Publicado: (2011)

Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review
por: D'Elia, John A., et al.
Publicado: (2016)

Cardiovascular mortality trends in Switzerland 1995–2018
por: Sorrentino, Lisa, et al.
Publicado: (2022)

Aldose Reductase: An Emerging Target for Development of Interventions for Diabetic Cardiovascular Complications
por: Jannapureddy, Sravya, et al.
Publicado: (2021)

Epicardial adipose tissue: an emerging biomarker of cardiovascular complications in type 2 diabetes?
por: Christensen, Regitse Højgaard, et al.
Publicado: (2020)

Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table
por: Doehner, Wolfram, et al.
Publicado: (2019)

Correlation Between Cardiovascular Protection and Influenza Vaccination
por: Ngwudike, Chinedu J., et al.
Publicado: (2023)

Distribution of echocardiographic parameters and their associations with cardiovascular risk factors in the Rotterdam Study
por: Kardys, Isabella, et al.
Publicado: (2010)

Impact of physical activity on the association of overweight and obesity with cardiovascular disease: The Rotterdam Study
por: Koolhaas, Chantal M, et al.
Publicado: (2017)

Genetic liability to insomnia in relation to cardiovascular diseases: a Mendelian randomisation study
por: Yuan, Shuai, et al.
Publicado: (2021)

Bone mineral density and risk of cardiovascular disease in men and women: the HUNT study
por: Bhatta, Laxmi, et al.
Publicado: (2021)

Sodium and potassium intake and risk of cardiovascular events and all-cause mortality: the Rotterdam Study
por: Geleijnse, Johanna M., et al.
Publicado: (2007)

Nonfasting triglycerides and risk of cardiovascular death in men and women from the Norwegian Counties Study
por: Lindman, Anja S., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ahvuh622utvofiitc6kegr03j0